JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Wednesday, Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has demonstrated strong revenue growth of 27.4% over the last twelve months, continues to show momentum. Truist analysts highlighted the positive growth trends for Eli Lilly’s Zepbound, noting an increase in prescription counts over the past 13 weeks.
The firm observed that since the beginning of the year, Zepbound has exhibited positive growth in script counts, while competing medication Wegovy has seen a decline in the same period. Specifically, in the most recent week, Zepbound total prescriptions (TRx) grew by 8% week-over-week, whereas Wegovy TRx decreased by 7%. According to InvestingPro, Eli Lilly maintains an impressive gross profit margin of 80.9% and has shown consistent financial strength with a "GOOD" overall health score.
In the broader diabetes GLP-1 market, Truist analysts reported that Ozempic remains the market leader, with Eli Lilly’s Mounjaro also continuing to expand its presence. Despite a week-over-week dip in Mounjaro TRx by 10%, compared to an 8% decline for Ozempic, the overall trend for Mounjaro is one of growth.
Truist Securities is looking forward to additional details on Eli Lilly’s performance, particularly concerning Zepbound and Mounjaro trends for the fiscal year 2025. Analysts are also anticipating further insights into the company’s supply and capacity issues during Eli Lilly’s fourth-quarter 2024 earnings call, scheduled for tomorrow.
In other recent news, Eli Lilly has seen a raised stock price target to $1,038 by Truist Securities following an updated fiscal year 2024 and announced fiscal year 2025 guidance. The pharmaceutical company anticipates FY2025 revenue to range from $58 to $61 billion, driven by products such as Jaypirca, Ebglyss, Omvoh, and Kisunla, along with the market expansion of Mounjaro. The company also plans to increase its production capacity, expecting to produce 60% more salable doses of incretins in the first half of 2025 compared to the first half of 2024.
In contrast, Tectonic Therapeutics has faced concerns after Eli Lilly terminated a similar drug study, leading to doubts about Tectonic’s TX45. Despite these concerns, Leerink Partners maintained their Outperform rating and a $69.00 price target on Tectonic.
Bernstein analysts also maintained an Outperform rating on Eli Lilly with a price target of $1,100, expressing confidence in the company’s prospects despite promising data from rival company Novo Nordisk (NYSE:NVO)’s phase 1b/2a trial of subcutaneous Amycretin. Similarly, BofA Securities reaffirmed a Buy rating on Eli Lilly with a $997 price target, even as competitor Novo Nordisk released preliminary data from a phase 1/2a study of a new weight loss drug. These are the recent developments in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.